메뉴 건너뛰기




Volumn 10, Issue 1, 2008, Pages 55-60

Exenatide as a treatment for diabetes and obesity: Implications for cardiovascular risk reduction

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; EXENDIN 4; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; GLYCOSYLATED HEMOGLOBIN; INCRETIN; INSULIN; INSULIN GLARGINE; METFORMIN; PLACEBO; SULFONYLUREA;

EID: 40749161446     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-008-0009-z     Document Type: Review
Times cited : (31)

References (44)
  • 1
    • 0035093810 scopus 로고    scopus 로고
    • Diabetes mellitus: A hypercoagulable state
    • Carr ME: Diabetes mellitus: a hypercoagulable state. J Diabetes Complications 2001, 15:44-54.
    • (2001) J Diabetes Complications , vol.15 , pp. 44-54
    • Carr, M.E.1
  • 2
    • 0032560807 scopus 로고    scopus 로고
    • Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction
    • Haffner SM, Lehto S, Ronnemaa T, et al.: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229-234.
    • (1998) N Engl J Med , vol.339 , pp. 229-234
    • Haffner, S.M.1    Lehto, S.2    Ronnemaa, T.3
  • 3
    • 0034994570 scopus 로고    scopus 로고
    • Healthy lifestyles in Europe: Prevention of obesity and type II diabetes by diet and physical activity
    • Astrup A: Healthy lifestyles in Europe: prevention of obesity and type II diabetes by diet and physical activity. Public Health Nutr 2001, 4:499-515.
    • (2001) Public Health Nutr , vol.4 , pp. 499-515
    • Astrup, A.1
  • 4
    • 18644365016 scopus 로고    scopus 로고
    • Insulin resistance in type 2 diabetes - role of the adipokines
    • Arner P: Insulin resistance in type 2 diabetes - role of the adipokines. Curr Mol Med 2005, 5:333-339.
    • (2005) Curr Mol Med , vol.5 , pp. 333-339
    • Arner, P.1
  • 5
    • 0030778116 scopus 로고    scopus 로고
    • The prevention and treatment of obesity. Application to type 2 diabetes
    • Maggio CA, Pi-Sunyer FX: The prevention and treatment of obesity. Application to type 2 diabetes. Diabetes Care 1997, 20:1744-1766.
    • (1997) Diabetes Care , vol.20 , pp. 1744-1766
    • Maggio, C.A.1    Pi-Sunyer, F.X.2
  • 6
    • 0032511583 scopus 로고    scopus 로고
    • Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group
    • Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352:837-853.
    • (1998) Lancet , vol.352 , pp. 837-853
  • 7
    • 1042280201 scopus 로고    scopus 로고
    • Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: A preliminary report
    • Koro CE, Bowlin SJ, Bourgeois N, Fedder DO: Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 2004, 27:17-20.
    • (2004) Diabetes Care , vol.27 , pp. 17-20
    • Koro, C.E.1    Bowlin, S.J.2    Bourgeois, N.3    Fedder, D.O.4
  • 8
    • 0033578476 scopus 로고    scopus 로고
    • Pharmacologic therapy for type 2 diabetes mellitus
    • DeFronzo RA: Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999, 131:281-303.
    • (1999) Ann Intern Med , vol.131 , pp. 281-303
    • DeFronzo, R.A.1
  • 9
    • 0022617246 scopus 로고
    • Reduced incretin effect in type 2 (non-insulin-dependent) diabetes
    • Nauck M, Stockmann F, Ebert R, Creutzfeldt W: Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986, 29:46-52.
    • (1986) Diabetologia , vol.29 , pp. 46-52
    • Nauck, M.1    Stockmann, F.2    Ebert, R.3    Creutzfeldt, W.4
  • 10
    • 0038497464 scopus 로고    scopus 로고
    • Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes
    • Kolterman OG, Buse JB, Fineman MS, et al.: Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003, 88:3082-3089.
    • (2003) J Clin Endocrinol Metab , vol.88 , pp. 3082-3089
    • Kolterman, O.G.1    Buse, J.B.2    Fineman, M.S.3
  • 11
    • 0027248866 scopus 로고
    • Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients
    • Nauck MA, Kleine N, Orskov C, et al.: Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993, 36:741-744.
    • (1993) Diabetologia , vol.36 , pp. 741-744
    • Nauck, M.A.1    Kleine, N.2    Orskov, C.3
  • 12
    • 9944251347 scopus 로고    scopus 로고
    • Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism
    • Nystrom T, Gonon AT, Sjoholm A, Pernow J: Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul Pept 2005, 125:173-177.
    • (2005) Regul Pept , vol.125 , pp. 173-177
    • Nystrom, T.1    Gonon, A.T.2    Sjoholm, A.3    Pernow, J.4
  • 13
    • 12144260853 scopus 로고    scopus 로고
    • Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury
    • Bose AK, Mocanu MM, Carr RD, et al.: Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005, 54:146-151.
    • (2005) Diabetes , vol.54 , pp. 146-151
    • Bose, A.K.1    Mocanu, M.M.2    Carr, R.D.3
  • 14
    • 1442311383 scopus 로고    scopus 로고
    • Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion
    • Nikolaidis LA, Mankad S, Sokos GG, et al.: Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004, 109:962-965.
    • (2004) Circulation , vol.109 , pp. 962-965
    • Nikolaidis, L.A.1    Mankad, S.2    Sokos, G.G.3
  • 15
    • 8544258807 scopus 로고    scopus 로고
    • Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease
    • Nystrom T, Gutniak MK, Zhang Q, et al.: Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004, 287:E1209-1215.
    • (2004) Am J Physiol Endocrinol Metab , vol.287
    • Nystrom, T.1    Gutniak, M.K.2    Zhang, Q.3
  • 16
    • 0037219411 scopus 로고    scopus 로고
    • Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes
    • Butler AE, Janson J, Bonner-Weir S, et al.: Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003, 52:102-110.
    • (2003) Diabetes , vol.52 , pp. 102-110
    • Butler, A.E.1    Janson, J.2    Bonner-Weir, S.3
  • 17
    • 0033303516 scopus 로고    scopus 로고
    • Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine
    • Hansen L, Deacon CF, Orskov C, Holst JJ: Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 1999, 140:5356-5363.
    • (1999) Endocrinology , vol.140 , pp. 5356-5363
    • Hansen, L.1    Deacon, C.F.2    Orskov, C.3    Holst, J.J.4
  • 18
    • 0141446228 scopus 로고    scopus 로고
    • Enhancing incretin action for the treatment of type 2 diabetes
    • Drucker DJ: Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003, 26:2929-2940.
    • (2003) Diabetes Care , vol.26 , pp. 2929-2940
    • Drucker, D.J.1
  • 19
    • 0031040794 scopus 로고    scopus 로고
    • Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard
    • Chen YE, Drucker DJ: Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard. J Biol Chem 1997, 272:4108-4115.
    • (1997) J Biol Chem , vol.272 , pp. 4108-4115
    • Chen, Y.E.1    Drucker, D.J.2
  • 20
    • 67649331128 scopus 로고    scopus 로고
    • Amylin Pharmaceuticals Inc, Available at, Accessed on June 25, 2007
    • Amylin Pharmaceuticals Inc.: Byetta: Prescribing Information. Available at http://www.byetta.com. Accessed on June 25, 2007.
    • Byetta: Prescribing Information
  • 21
    • 0036235563 scopus 로고    scopus 로고
    • Endoproteolysis by isolated membrane peptidases reveal metabolic stability of glucagon-like peptide-1 analogs, exendins-3 and -4
    • Thum A, Hupe-Sodmann K, Goke R, et al.: Endoproteolysis by isolated membrane peptidases reveal metabolic stability of glucagon-like peptide-1 analogs, exendins-3 and -4. Exp Clin Endocrinol Diabetes 2002, 110:113-118.
    • (2002) Exp Clin Endocrinol Diabetes , vol.110 , pp. 113-118
    • Thum, A.1    Hupe-Sodmann, K.2    Goke, R.3
  • 22
    • 0035340019 scopus 로고    scopus 로고
    • Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro
    • Parkes DG, Pittner R, Jodka C, et al.: Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism 2001, 50:583-589.
    • (2001) Metabolism , vol.50 , pp. 583-589
    • Parkes, D.G.1    Pittner, R.2    Jodka, C.3
  • 23
    • 7444228521 scopus 로고    scopus 로고
    • Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonyl-urea-treated patients with type 2 diabetes
    • Buse JB, Henry RR, Han J, et al.: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonyl-urea-treated patients with type 2 diabetes. Diabetes Care 2004, 27:2628-2635.
    • (2004) Diabetes Care , vol.27 , pp. 2628-2635
    • Buse, J.B.1    Henry, R.R.2    Han, J.3
  • 24
    • 18144401971 scopus 로고    scopus 로고
    • Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes
    • DeFronzo RA, Ratner RE, Han J, et al.: Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005, 28:1092-1100.
    • (2005) Diabetes Care , vol.28 , pp. 1092-1100
    • DeFronzo, R.A.1    Ratner, R.E.2    Han, J.3
  • 25
    • 20544476444 scopus 로고    scopus 로고
    • Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: A dose-ranging study
    • Poon T, Nelson P, Shen L, et al.: Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study. Diabetes Technol Ther 2005, 7:467-477.
    • (2005) Diabetes Technol Ther , vol.7 , pp. 467-477
    • Poon, T.1    Nelson, P.2    Shen, L.3
  • 26
    • 4344713643 scopus 로고    scopus 로고
    • Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia
    • Degn KB, Brock B, Juhl CR, et al.: Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes 2004, 53:2397-2403.
    • (2004) Diabetes , vol.53 , pp. 2397-2403
    • Degn, K.B.1    Brock, B.2    Juhl, C.R.3
  • 27
    • 17144371646 scopus 로고    scopus 로고
    • Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea
    • Kendall DM, Riddle MC, Rosenstock J, et al.: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005, 28:1083-1091.
    • (2005) Diabetes Care , vol.28 , pp. 1083-1091
    • Kendall, D.M.1    Riddle, M.C.2    Rosenstock, J.3
  • 28
    • 26944477362 scopus 로고    scopus 로고
    • Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: A randomized trial
    • Heine RJ, Van Gaal LF, Johns D, et al.: Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005, 143:559-569.
    • (2005) Ann Intern Med , vol.143 , pp. 559-569
    • Heine, R.J.1    Van Gaal, L.F.2    Johns, D.3
  • 29
    • 33748442464 scopus 로고    scopus 로고
    • Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes
    • Blonde L, Klein EJ, Han J, et al.: Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006, 8:436-447.
    • (2006) Diabetes Obes Metab , vol.8 , pp. 436-447
    • Blonde, L.1    Klein, E.J.2    Han, J.3
  • 30
    • 0034641568 scopus 로고    scopus 로고
    • Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study
    • Stratton IM, Adler AI, Neil HA, et al.: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321:405-412.
    • (2000) BMJ , vol.321 , pp. 405-412
    • Stratton, I.M.1    Adler, A.I.2    Neil, H.A.3
  • 31
    • 0032902850 scopus 로고    scopus 로고
    • The relationship between glucose and incident cardiovascular events. A meta-regression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years
    • Coutinho M, Gerstein HC, Wang Y, Yusuf S: The relationship between glucose and incident cardiovascular events. A meta-regression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999, 22:233-240.
    • (1999) Diabetes Care , vol.22 , pp. 233-240
    • Coutinho, M.1    Gerstein, H.C.2    Wang, Y.3    Yusuf, S.4
  • 32
    • 33749046314 scopus 로고    scopus 로고
    • Postprandial hyperglycaemia and cardiovascular complications of diabetes: An update
    • Ceriello A, Davidson J, Hanefeld M, et al.: Postprandial hyperglycaemia and cardiovascular complications of diabetes: an update. Nutr Metab Cardiovasc Dis 2006, 16:453-456.
    • (2006) Nutr Metab Cardiovasc Dis , vol.16 , pp. 453-456
    • Ceriello, A.1    Davidson, J.2    Hanefeld, M.3
  • 33
    • 22744439545 scopus 로고    scopus 로고
    • Contributions of basal and post-prandial hyperglycaemia to micro- and macrovascular complications in people with type 2 diabetes
    • Home P: Contributions of basal and post-prandial hyperglycaemia to micro- and macrovascular complications in people with type 2 diabetes. Curr Med Res Opin 2005, 21:989-998.
    • (2005) Curr Med Res Opin , vol.21 , pp. 989-998
    • Home, P.1
  • 34
    • 0031880436 scopus 로고    scopus 로고
    • Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. The Rancho Bernardo Study
    • Barrett-Connor E, Ferrara A: Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. The Rancho Bernardo Study. Diabetes Care 1998, 21:1236-1239.
    • (1998) Diabetes Care , vol.21 , pp. 1236-1239
    • Barrett-Connor, E.1    Ferrara, A.2
  • 35
    • 0033047374 scopus 로고    scopus 로고
    • Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study
    • Tominaga M, Eguchi H, Manaka H, et al.: Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999, 22:920-924.
    • (1999) Diabetes Care , vol.22 , pp. 920-924
    • Tominaga, M.1    Eguchi, H.2    Manaka, H.3
  • 36
    • 0027365368 scopus 로고
    • Long-term effects of change in body weight on all-cause mortality. A review
    • Andres R, Muller DC, Sorkin JD: Long-term effects of change in body weight on all-cause mortality. A review. Ann Intern Med 1993, 119:737-743.
    • (1993) Ann Intern Med , vol.119 , pp. 737-743
    • Andres, R.1    Muller, D.C.2    Sorkin, J.D.3
  • 37
    • 31644444063 scopus 로고    scopus 로고
    • The growing problem of obesity and the heart: The plot "thickens
    • Litwin SE: The growing problem of obesity and the heart: the plot "thickens". J Am Coll Cardiol 2006, 47:617-619.
    • (2006) J Am Coll Cardiol , vol.47 , pp. 617-619
    • Litwin, S.E.1
  • 39
    • 0025317085 scopus 로고
    • A prospective study of obesity and risk of coronary heart disease in women
    • Manson JE, Colditz GA, Stampfer MJ, et al.: A prospective study of obesity and risk of coronary heart disease in women. N Engl J Med 1990, 322:882-889.
    • (1990) N Engl J Med , vol.322 , pp. 882-889
    • Manson, J.E.1    Colditz, G.A.2    Stampfer, M.J.3
  • 40
    • 0027520177 scopus 로고
    • Body weight and mortality. A 27-year follow-up of middle-aged men
    • Lee IM, Manson JE, Hennekens CH, Paffenbarger RS Jr: Body weight and mortality. A 27-year follow-up of middle-aged men. JAMA 1993, 270:2823-2828.
    • (1993) JAMA , vol.270 , pp. 2823-2828
    • Lee, I.M.1    Manson, J.E.2    Hennekens, C.H.3    Paffenbarger Jr, R.S.4
  • 41
    • 0026753155 scopus 로고
    • Beneficial health effects of modest weight loss
    • Goldstein DJ: Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 1992, 16:397-415.
    • (1992) Int J Obes Relat Metab Disord , vol.16 , pp. 397-415
    • Goldstein, D.J.1
  • 42
    • 0033807248 scopus 로고    scopus 로고
    • Intentional weight loss and mortality among overweight individuals with diabetes
    • Williamson DF, Thompson TJ, Thun M, et al.: Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000, 23:1499-1504.
    • (2000) Diabetes Care , vol.23 , pp. 1499-1504
    • Williamson, D.F.1    Thompson, T.J.2    Thun, M.3
  • 43
    • 33748471110 scopus 로고    scopus 로고
    • Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus
    • Ratner RE, Maggs D, Nielsen LL, et al.: Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab 2006, 8:419-428.
    • (2006) Diabetes Obes Metab , vol.8 , pp. 419-428
    • Ratner, R.E.1    Maggs, D.2    Nielsen, L.L.3
  • 44
    • 33845267926 scopus 로고    scopus 로고
    • Exenatide treatment for 82 weeks reduced C-reactive protein, HbA1C, and body weight in patients with type 2 diabetes mellitus [abstract 784]
    • Kendall DM, Bhole D, Guan X, et al.: Exenatide treatment for 82 weeks reduced C-reactive protein, HbA1C, and body weight in patients with type 2 diabetes mellitus [abstract 784]. Diabetologia 2006, 49(Suppl 1):475.
    • (2006) Diabetologia , vol.49 , Issue.SUPPL. 1 , pp. 475
    • Kendall, D.M.1    Bhole, D.2    Guan, X.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.